Saturday, December 7, 2013

Return of the malingering mutants


 2013 Sep 17;109(6):1391-3. doi: 10.1038/bjc.2013.490. Epub 2013 Sep 3.

Return of the malingering mutants.

Source

Center for Evolution and Cancer, The Institute of Cancer Research, Brookes Lawley Building, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

"Of all the hallmark biological features of cancer, drug resistance stands out as the harbinger of bad news for patients and oncologists alike. Cancer cells can employ several adaptive mechanisms for evading chemotherapeutic assault () (Table 1). Prominent among these is mutation of the gene(s) encoding the drug targets. Unambiguous and consistent evidence for this route to escape has been provided in the recent era of therapy with small-molecule tyrosine kinase inhibitors (TKIs) ()."

No comments:

Post a Comment